Why Nektar Therapeutics’s (NKTR) Stock Is Down 5.72%
As of Friday, July 10, Nektar Therapeutics’s NKTR share price has dipped by 5.72%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Commentary & Analysis
Why Nektar Therapeutics’s (NKTR) Stock Is Up 6.29%
As of Tuesday, June 30, Nektar Therapeutics’s NKTR share price has surged by 6.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Nektar Therapeutics’s (NKTR) Stock Is Up 6.77%
As of Monday, June 22, Nektar Therapeutics’s NKTR share price has surged by 6.77%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Which Is a Better Investment, Nektar Therapeutics or Trulieve Cannabis Corp. Stock?
Learn more about whether Nektar Therapeutics or Trulieve Cannabis Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why Nektar Therapeutics’s (NKTR) Stock Is Down 5.83%
As of Tuesday, June 02, Nektar Therapeutics’s NKTR share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,544.7 | $618.0 | 57% |
|
| Shares Out (Mil) | 33.1 | 44.8 | 38% |
|
| Institutional Ownership | 99.5% | 85.3% | 89% |
|
| Float (Mil) | 28.5 | 47.4 | 35% |
|
| Beta | 1.16 | 0.70 | 69% |
|
| Avg Daily Volume (000s) | 613 | 390 | 61% |
|
| Price Change (52-week) |
178.9% | 68.6% | 96% |
|
| Growth | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (18.4%) | 6.7% | 3% |
|
| Net Income (5yr) | 18.1% | (1.6%) | 70% |
|
| EPS (5yr) | 23.6% | 14.9% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (14.9%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 5 | |
| Current EPS | ($2.258) | ($8.465) | ($10.844) | |
| Month Ago EPS | ($0.515) | ($9.543) | ($12.563) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.515) | ($9.543) | ($12.563) | |
| Year/Year Chg | 83.7% | (13.0%) | 22.1% | |
| Financials | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $55 | $291 | 21% |
|
| Net Income (TTM) (Mil) | ($157) | ($11) | 8% |
|
| EPS (TTM) | ($6.468) | ($0.700) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($234) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $5 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $113 | $6 | 45% |
|
| Enterprise Value (Q1) (Mil) | $1,945 | $450 | 49% |
|
| Valuation | NKTR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.82 | 2.78 | 62% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NKTR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.0% | 96% |
|
| Net Margin | (287.8%) | (2.3%) | 3% |
|
| ROA | (24.1%) | (22.4%) | 19% |
|
| ROE | (35.8%) | (20.2%) | 18% |
|
| Liabilities to Assets | 17.5% | 32.2% | 11% |
|
| F-Score | 3 | 3 | 18% |
|
Nektar Therapeutics did not pass any screens on 8/20/2026.
